Autocrine production of interleukin 1β confers constitutive nuclear factor κB activity and chemoresistance in pancreatic carcinoma cell lines

Cancer Research

Volumn 62, Issue 3, 2002, Pages 910-916

  Arlt, Alexander ^a   Vorndamm, Jens ^a   Müerköster, Susanne ^a   Yu, Honggang ^b   Schmidt, Wolfgang E ^b   Fölsch, Ulrich R ^a   Schäfer, Heiner ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b ST JOSEF HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 ANTIBODY; INTERLEUKIN 1BETA; SALAZOSULFAPYRIDINE;

APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; CANCER RESISTANCE; CHEMOSENSITIVITY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; PANCREAS CARCINOMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; DNA DAMAGE; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; HUMANS; INTERLEUKIN-1; NF-KAPPA B; PANCREATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0036468297     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Control of apoptosis by Rel/NF-κB transcription factors
2. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-κB activation prevents cell death
3. Rel blocks both anti-Fas- and TNF-α-induced apoptosis and an intact Rel transactivation domain is essential for this effect
4. TNF- and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-κB
5. Inhibition of nuclear factor κB activation attenuates apoptosis resistance in lymphoid cells
6. Salicylates inhibit NF-κB activation and enhance TNF-α-induced apoptosis in human pancreatic cancer cells
7. Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB
8. The nuclear factor-κB RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells
9. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB
10. Inhibition of NF-κB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin
11. NF-κB and Rel proteins: Evolutionarily conserved mediators of immune responses
12. How NF-κB is activated: The role of the IκB kinase (IKK) complex
13. Aberrant nuclear factor-κB/Rel expression and the pathogenesis of breast cancer
14. Constitutive nuclear factor-κB-RelA activation is required for proliferation and survival of Hodgkin’s disease tumor cells
15. Molecular mechanisms of constitutive NF-κB/Rel activation in Hodgkin/Reed-Sternberg cells
16. A requirement for NF-κB activation in Bcr-Abl-mediated transformation
17. Regulation of NF-κB activity by IκB-related proteins in adenocarcinoma cells
18. Nuclear factor-κB is constitutively active in C-cell carcinoma and required for RET-induced transformation
19. Inhibition of NF-κB sensitizes non-small cell lung cancer cells to chemotherapy-induced apoptosis
20. The transcription factor NF-κB: Control of oncogenesis and cancer therapy resistance
21. Involvement of regulatory and catalytic subunits of phosphoinositide 3-kinase in NF-κB activation
22. Overexpression of IκBα without inhibition of NF-κB activity and mutations in the IκBα gene in Reed Sternberg cells
23. Akt stimulates the transactivation potential of the RelA/p65 subunit of NF-κB through utilization of the IκB kinase and activation of the mitogen-activated protein kinase p38
24. Aberrant rel/nfkb genes and activity in human cancer
25. Constitutive activation of NF-KB causes resistance to apoptosis in human cutaneous T cell lymphoma HuT-78 cells. Autocrine role of tumor necrosis factor and reactive oxygen intermediates
26. Interleukin-1 protects transformed keratinocytes from turnor necrosis factor-related apoptosis-inducing ligand
27. Raf-induced transformation requires an interleukin 1 autocrine loop
28. Constitutive IκB kinase activity correlates with nuclear factor-κB activation in human melanoma cells
29. IL-1α promotes NF-κB and AP-1-induced 1L-8 expression, cell survival and proliferation in head and neck squamous cell carcinomas
30. p53 and K-RAS alterations in pancreatic epithelial cell lesions
31. The putative apoptosis inhibitor IEX-1L is a mutant nonspliced variant of p22(PRG1/IEX-1) and is not expressed in vivo
32. The promoter of human p22/PACAP response gene 1 (PRG1) functional binding sites for the p53 tumor suppressor and for NFκB
33. Molecular effects of topoisomerase 11 inhibitors in AML cell lines: Correlation of apoptosis with topoisomerase 11 activity but not with DNA damage
34. Role of the IκB kinase complex in oncogenic Ras- and Raf-mediated transformation of rat liver epithelial cells
35. Oncogcnic Ras enhances NF-κB transcriptional activity through Raf-dependent and Raf-independent mitogen-activated protein kinase signaling pathways
36. Genetic profile of 22 pancreatic carcinoma cell lines
37. Investigation of the mechanism of higher order chromatin fragmentation observed in drug-induced apoptosis
38. B-lineage lymphoid blast crisis in juvenile chronic myelogenous leukemia. II. Interleukin-1-mediated autocrine growth regulation of the lymphoblasts
39. Establishment of human acute myelogenous leukemia lines secreting interleukin-1β in SCID mice
40. Distinct patterns of expression of interleukin-1 α and β by normal and cancerous human ovarian tissues
41. Development of human prostate cancer cells to neuroendocrine-like cells by interleukin-1
42. Autocrine interleukin-1β production in leukemia: Evidence for the involvement of mutated RAS
43. Effects of ILI-α, IL-1 receptor antagonist and neutralizing antibody on proinflammatory cytokine expression by human squamous carcinoma lines
44. Cisplatin and radiation sensitivity in human head and neck squamous carcinomas are independently modulated by glutathione and transcription factor NF-κB
45. A Phase I study of recombinant human soluble interleukin-1 receptor (rhu IL-IR) in patients with relapsed and refractory acute myeloid leukemia